Abstract:Fragment approaches are long-established in target-based ligand discovery. Nevertheless, their full transformative potential lies dormant, because progressing hits to potency remains difficult and underserved by methodology developments, which mostly focus on screening. The only credible progression paradigm is conventional design-make-test analyse (DMTA) medicinal chemistry, which is costly and thus necessitates picking winners early, thereby effectively discarding all the other hits. We here demonstrate the workability of an alternative strategy, namely immediate large-scale exploration of diverse hit-inspired compounds. The key insight is that it is effective to cheaply parallelize large numbers of non-uniform multi-step reactions, because even without compound purification, a high-quality readout of binding is available, namely crystallography of fragment screening. This has the sensitivity to detect even low-level binding of slightly active compounds, which the targeted binding site extracts directly from crude reaction mixtures (CRMs). In this proof-of-concept study, we expand a fragment hit from a crystal-based screen of the second bromodomain of human PHIP, using array synthesis on low-cost robotics to implement 6 independent multi-step reaction routes of up to 5 steps, attempting the synthesis of 1876 diverse expansions; designs were entirely driven by synthetic tractability. Expected product was present in 1108 CRMs, as detected by automated mass spectrometry; and 22 individual products were resolved in crystal structures of CRMs added to crystals. These provided an initial SAR map, revealed pose stability in 19 and instability in 3 products, and resolved stereochemical preference. Unexpectedly, in view of the naïve design approach, one resolved compound even showed on-scale biochemical potency (IC50=34 μM) and biophysical affinity (Kd=50 μM) after resynthesis. This binding-site purification of actives (B-SPA) process is formulaic and engineerable, here yielding the output of >25 person-years in ~20 days, with solvent use reduced from >4,500L to <20L. Thus, this approach, coupled with algorithmically guided compound and reaction design and new formalisms for data analysis, lends itself to routine fragment progression.

Efficiently driving protein-based fragment screening and lead discovery using two-dimensional NMR

Automated Fragmentation QM/MM Calculation of NMR Chemical Shifts for Protein-Ligand Complexes.

Recent progress in fragment-based drug discovery facilitated by NMR spectroscopy

Process of Fragment-Based Lead Discovery—A Perspective from NMR

Fast Quantitative Validation of 3D Models of Low-Affinity Protein-Ligand Complexes by STD NMR Spectroscopy

Combining Automated Peak Tracking in SAR by NMR with Structure-Based Backbone Assignment from 15N-NOESY

Applications of NMR screening techniques to the pharmaceutical target Checkpoint kinase 1

NMR Characterization of Weak Interactions Between RhoGDI2 and Fragment Screening Hits

A Novel NMR-Based Protocol to Screen Ultralow Molecular Weight Fragments

Perspectives on Applications of 19F-NMR in Fragment-Based Drug Discovery

Protocol to perform fragment screening using NMR spectroscopy

Accelerated Screening of Protein-Ligand Interactions via Parallel T 2 -Weighted 19 F-MRI

Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation

Efficient large-scale exploration of fragment hit progression by exploiting binding-site purification of actives (B-SPA) through combining multi-step array synthesis and HT crystallography.

A combination of spin diffusion methods for the determination of protein-ligand complex structural ensembles.

Rational design of F NMR labelling sites to probe protein structure and interactions

Structure-based drug design: NMR-based approach for ligand-protein interactions.

A fragment based competitive 19F LB‐NMR platform for hotspot directed ligand profiling

Rapid Characterization of Structural and Behavioral Changes of Therapeutic Proteins by Relaxation and Diffusion 1H-SOFAST NMR Experiments

A Ligand-observed Mass Spectrometry Approach Integrated into the Fragment Based Lead Discovery Pipeline

Fragment-based screening of enzyme drug targets : Microfluidic mobility shift assay improves confidence in candidate selection